Hillstream BioPharma, Inc. announced pharmacokinetic (PK) data of HSB-1216 supportive of its development strategy and pre-clinical data. These data suggest Quatramer protects HSB-1216 from metabolic degradation until its release at the tumor site and is consistent with the promising efficacy data demonstrating effective reduction of tumor growth in pre-clinical studies. The preliminary safety and PK of HSB-1216 was evaluated in IND-enabling studies using rats and dogs showing the Quatramer bound HSB-1216 throughout a 48-hour exposure period prevented degradation in the in systemic circulation until its targeted release at the tumor site.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.745 USD | +5.69% | +3.76% | -37.85% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-37.85% | 37.29L | |
+11.60% | 11TCr | |
-4.68% | 2.43TCr | |
-0.82% | 2.2TCr | |
-10.12% | 1.82TCr | |
-42.12% | 1.64TCr | |
-17.47% | 1.56TCr | |
+2.77% | 1.36TCr | |
+34.58% | 1.23TCr | |
+77.64% | 887.31Cr |
- Stock Market
- Equities
- THAR Stock
- News Tharimmune, Inc.
- Hillstream BioPharma, Inc. Announces Pharmacokinetic Data of HSB-1216 Supportive of its Development Strategy and Pre-clinical Data